Streetbeat News

Revenues

SYK

Stryker Corporation, a medical technologies firm, has achieved a significant milestone by surpassing $20 billion in sales for the year 2023. This accomplishment reflects the company's growth and success in the market.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 1:01 pm

CRDO

Six analysts have recently provided their ratings on Credo Technology Group (NASDAQ:CRDO), with all six maintaining a bullish stance. Over the past three months, there has been a positive shift in sentiment, with the average 12-month price target for CRDO increasing by 23.24% to $23.17. Analysts from firms including Needham, Goldman Sachs, Stifel, and Mizuho have raised their price targets, reflecting optimism about the company's prospects. Despite this, CRDO faces challenges with a -14.28% revenue decline, a net margin of -15.04%, and an ROA of -1.65%, indicating potential difficulties in profitability and asset utilization. However, a strong ROE of -1.9% and a low debt-to-equity ratio of 0.04 suggest effective use of equity and a healthy balance sheet.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 1:00 pm

VOYA

Voya Financial (NYSE:VOYA) received mixed analyst ratings in the latest quarter, with 3 somewhat bullish and 1 indifferent rating. The average 12-month price target is $84.00, with a high of $85.00 and a low of $82.00, marking a decrease from the previous $88.00 target. Analysts from Goldman Sachs, RBC Capital, Morgan Stanley, and Wells Fargo have provided recent evaluations, with two maintaining and two lowering their price targets. Voya Financial's financial performance shows a 31.29% revenue growth rate, a net margin of 13.94%, an ROE of 7.27%, an ROA of 0.16%, and a debt-to-equity ratio of 1.1.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 1:00 pm

RXST

Analysts have mixed views on RxSight (NASDAQ:RXST), with 5 recent ratings ranging from bullish to somewhat bullish. The average 12-month price target is $37.8, up 6.48% from the previous $35.50. Analysts from Needham, Wells Fargo, Stifel, and Morgan Stanley have provided ratings and price targets, with Needham's David Saxon both raising and lowering his target. RxSight, a medical technology company, has shown a revenue growth of 75.97% as of September 30, 2023, but struggles with profitability and efficiency, as indicated by its net margin of -55.93%, ROE of -7.79%, and ROA of -6.58%. Its low debt-to-equity ratio of 0.02 suggests a healthy balance of debt and equity.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 1:00 pm

DASH

DoorDash (NASDAQ:DASH) received mixed analyst ratings in the latest quarter with 9 analysts offering their perspectives. The average 12-month price target for DASH is $104.11, a 15.31% increase from the previous target of $90.29. Analysts from firms like Jefferies, Deutsche Bank, and Needham have given bullish ratings with price targets ranging from $105.00 to $130.00. Others like Piper Sandler and Barclays have given more conservative ratings. DoorDash's financials show a strong market presence with a market cap above industry benchmarks, a positive revenue trend with 27.22% growth, but below-average net margin, ROE, and ROA. The company's debt-to-equity ratio is low at 0.08.

Portfolio Pulse from Benzinga Insights

January 08, 2024 | 1:00 pm

AXNX

Axonics anticipates its FY23 revenues to be around $366.1M, marking a 34% year-over-year increase, which slightly exceeds the consensus estimate of $362.27M. The company expects sacral neuromodulation revenue to grow by 31% to $291.7M and Bulkamid revenue to increase by 44% to $74.4M compared to fiscal year 2022.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:59 pm

GOOG

GOOGL

LLY

NVS

Isomorphic Labs, an Alphabet Inc spin-off, has partnered with Eli Lilly and Novartis AG for AI-driven drug discovery. The deals are valued at around $3 billion, with Isomorphic receiving $45 million upfront from Eli Lilly and potentially $1.7 billion in milestones, and $37.5 million upfront from Novartis with up to $1.2 billion in incentives. Isomorphic uses DeepMind's AlphaFold 2 AI for predicting protein structures, aiding in drug design. Despite a £2.4 million loss in 2021, Isomorphic is expanding, including a new Swiss office. Google Cloud also launched AI tools for healthcare data consolidation.

Portfolio Pulse from Anusuya Lahiri

January 08, 2024 | 12:58 pm

AXNX

Axonics anticipates Q4 FY23 revenues to range between $109.3M and $109.7M, marking a 27% year-over-year increase, surpassing the consensus estimate of $105.56M. Sacral neuromodulation revenue is expected to rise by 26% to $88.3M-$88.5M, while Bulkamid revenue is projected to grow by 35% to $21.0M-$21.2M.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:58 pm

APYX

Apyx Medical announced preliminary FY23 revenues of approximately $51.9M-$52.3M, reflecting a 17%-18% increase year-over-year, but slightly below the consensus estimate of $53.25M. The Advanced Energy segment is expected to generate $43.1M-$43.5M, up 17%-18% Y/Y, while OEM revenue is projected at $8.8M, up 14% Y/Y.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:54 pm

APYX

Apyx Medical announced preliminary Q4 revenues of approximately $14.2M-$14.6M, reflecting a year-over-year increase of 13%-16%, which falls short of the consensus estimate of $15.58M. The Advanced Energy segment is expected to report revenue growth of 12%-16%, while OEM revenue is projected to grow by 14% compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

January 08, 2024 | 12:51 pm